Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-info
TL;DR
Keros Therapeutics filed a routine 8-K on 8/20/25. No major news yet.
AI Summary
On August 20, 2025, Keros Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices located in Lexington, Massachusetts. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing serves as a notification to the SEC and the public about the company's status and corporate information. It is a standard procedural filing for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard procedural 8-K and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- August 20, 2025 (date) — Date of earliest event reported
- Lexington, Massachusetts (location) — Principal executive offices
- 001-39264 (other) — Commission File Number
- 81-1173868 (other) — I.R.S. Employer Identification No.
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 20, 2025.
What is the full legal name of the registrant?
The full legal name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the address of the principal executive offices?
The address of the principal executive offices is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the telephone number of the registrant, including area code?
The registrant's telephone number, including area code, is (617) 314-6297.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-08-20 09:50:45
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20250820.htm (8-K) — 37KB
- exhibit99182025pr.htm (EX-99.1) — 11KB
- 0001664710-25-000073.txt ( ) — 211KB
- kros-20250820.xsd (EX-101.SCH) — 2KB
- kros-20250820_def.xml (EX-101.DEF) — 17KB
- kros-20250820_lab.xml (EX-101.LAB) — 28KB
- kros-20250820_pre.xml (EX-101.PRE) — 17KB
- kros-20250820_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 20, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 20 , 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: August 20, 2025